Stopped: contract never completed
The purpose of this study is to determine the efficacy of RetroPerc® in obtaining renal access for percutaneous nephrolithotomy
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Treatment efficacy as measured by the time taken from diagnosis to nephrostomy access
Timeframe: end of procedure (about 4-8 weeks from diagnosis)
Treatment efficacy as measured by total time of access operation.
Timeframe: end of procedure( about 90 minutes after start of procedure)
Treatment efficacy as measured by total time of access operation fluoroscopy
Timeframe: end of procedure( about 90 minutes after start of procedure)
Treatment efficacy as measured by total time of lithotomy operation
Timeframe: end of procedure(about 3 hours after start of procedure)
Treatment efficacy as measured by total time of lithotomy operation fluoroscopy
Timeframe: (end of procedure)about 3 hours after start of procedure
Treatment efficacy as measured by length of post-operative hospital stay
Timeframe: 24 hours after procedure
Number of patients that are stone free
Timeframe: 6-12 weeks after procedure
Number of patients with symptom free survival as defined as lack of flank pain
Timeframe: 6-12 weeks after procedure
Number of patients with symptom free survival as defined as lack of presence of urinary or gastrointestinal symptoms,
Timeframe: 6-12 weeks after procedure
Number of patients with symptom free survival as defined as lack of limitations to work
Timeframe: 6-12 weeks after procedure
Number of patients with symptom free survival as defined as lack of limitations to social or daily activities.
Timeframe: 6-12 weeks after procedure